



ARKANSAS
DEPARTMENT OF
**HUMAN
SERVICES**

**Division of Medical Services
Medicaid Pharmacy Program**

P.O. Box 1437, Slot S415, Little Rock, AR 72203-1437
P: 501.683.4120 F: 800-424-5851

April 27, 2026

RE: Updates for Vyvanse® capsules and chew tablets and Briviact® tablets

Prescribers and pharmacists,

Vyvanse® (lisdexamfetamine dimeslate) capsule/chew tablet and Briviact® (brivaracetam) tablet have been brand preferred for quite some time. **Effective 4/29/2026**, both the generic and the brand products will be available for dispensing to Arkansas Medicaid beneficiaries.

Generic lisdexamfetamine and generic brivaracetam will require DAW code of zero (0) to process the payment at the correct generic rate. Brand Vyvanse® and brand Briviact® will require a DAW code of nine (9) to ensure the claim is processed as a plan prefers brand (PPB) product and pays at the brand rate. **After 05/31/2026**, brand Briviact® will no longer be considered the plan preferred brand product while the generic will become the preferred option if approved with a prior authorization as brivaracetam is a non-preferred product. The overlap of brand and generic will allow pharmacies to exhaust the brand product inventory.

Both brand and generic Vyvanse® (lisdexamfetamine dimeslate) capsule and chew tablets will remain as preferred options until further notice due to drug shortages. We request the pharmacy to dispense generic lisdexamfetamine when possible.

For any questions, contact the Prime Therapeutics Help Desk at 800-424-7895.

Sincerely,

Cynthia Neuhofel, Pharm.D.
DMS Assistant Director/Pharmacy Director